As of 26 May 2025, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of Japanese encephalitis vaccine for the prevention of Japanese encephalitis among children 9 to 59 months old in high risk areas as defined in the DOH Omnibus Health Guidelines (OHG) for Children under 10 years (2023), continue reading : HTA Council Preliminary Recommendation on Japanese Encephalitis Vaccine (JEV)
HTA Council Preliminary Recommendation on Human Immunodeficiency Virus (HIV) Self Test Kit, HIV/Syphilis Duo Test, In Vitro Quantitative HIV Nucleic Acid Test (HIV-NAT 1), and Silver Diamine Fluoride 38% Clear Topical Solution
As of 26 May 2025, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of the following health technologies for possible government financing: These health technologies were reviewed against clinical practice guidelines (CPGs) [local and approved by the DOH, such as the DOH Omnibus Health Guidelines (OHG); and/or international, but locally continue reading : HTA Council Preliminary Recommendation on Human Immunodeficiency Virus (HIV) Self Test Kit, HIV/Syphilis Duo Test, In Vitro Quantitative HIV Nucleic Acid Test (HIV-NAT 1), and Silver Diamine Fluoride 38% Clear Topical Solution
HTA Council Preliminary Recommendation on ticagrelor [90mg film-coated tablet] as an add-on to aspirin for adults with acute coronary syndrome (ACS)
Update as of 21 May 2025 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Ticagrelor [90mg film-coated tablet] as an add-on to aspirin for adults with acute coronary syndrome (ACS) ended on 19 May 2025 without any appeals received, this preliminary HTA Council recommendation lapsed into the Final Recommendation and was transmitted to continue reading : HTA Council Preliminary Recommendation on ticagrelor [90mg film-coated tablet] as an add-on to aspirin for adults with acute coronary syndrome (ACS)
HTA Council Preliminary Recommendation on Tetanus, Diptheria, and Acellular Pertussis (Tdap) Vaccine as booster immunization against tetanus, diptheria, and pertussis for Grade 1 students (6-7 years old, Grade 7 students (11-12 years old) and pregnant women
Update as of 26 May 2025 : The public consultation and appeals period for the HTA Council Preliminary Recommendation on Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine as booster immunization against tetanus, diphtheria, and pertussis for Grade 1 students (6-7 years old), Grade 7 students (11-12 years old) and pregnant women ended on 19 May 2025. Having received continue reading : HTA Council Preliminary Recommendation on Tetanus, Diptheria, and Acellular Pertussis (Tdap) Vaccine as booster immunization against tetanus, diptheria, and pertussis for Grade 1 students (6-7 years old, Grade 7 students (11-12 years old) and pregnant women
HTA Council Preliminary Recommendation on Ceftaroline Fosamil (600 mg powder for concentrate for solution for injection) in the Treatment of Community-Acquired Pneumonia (CAP) in Children
Update as of 14 May 2025 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Ceftaroline Fosamil (600 mg powder for concentrate for solution for injection) in the Treatment of Community-Acquired Pneumonia (CAP) in Children ended on 13 May 2025 without any appeals received, this preliminary HTA Council recommendation lapsed into the Final continue reading : HTA Council Preliminary Recommendation on Ceftaroline Fosamil (600 mg powder for concentrate for solution for injection) in the Treatment of Community-Acquired Pneumonia (CAP) in Children